Zacks Research Has Negative Estimate for Neogen Q2 Earnings

Neogen Co. (NASDAQ:NEOG) – Investment analysts at Zacks Research cut their Q2 2025 EPS estimates for Neogen in a report issued on Thursday, January 2nd. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.11 for the quarter, down from their prior estimate of $0.12. The consensus estimate for Neogen’s current full-year earnings is $0.50 per share. Zacks Research also issued estimates for Neogen’s FY2027 earnings at $0.72 EPS.

NEOG has been the topic of a number of other research reports. Guggenheim began coverage on shares of Neogen in a research report on Thursday, December 19th. They issued a “buy” rating and a $15.00 price objective on the stock. StockNews.com raised Neogen to a “sell” rating in a report on Monday, September 30th.

Neogen Stock Performance

Shares of NASDAQ:NEOG opened at $12.73 on Monday. The company has a quick ratio of 2.79, a current ratio of 4.41 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $2.76 billion, a price-to-earnings ratio of -115.73 and a beta of 1.23. Neogen has a 52 week low of $11.46 and a 52 week high of $19.88. The firm has a 50 day moving average of $13.62 and a 200 day moving average of $15.16.

Neogen (NASDAQ:NEOG) last issued its earnings results on Thursday, October 10th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Neogen had a positive return on equity of 2.80% and a negative net margin of 2.58%. The firm had revenue of $217.00 million during the quarter, compared to analysts’ expectations of $215.05 million. During the same quarter in the prior year, the company posted $0.11 earnings per share. Neogen’s quarterly revenue was down 5.2% compared to the same quarter last year.

Institutional Investors Weigh In On Neogen

A number of hedge funds and other institutional investors have recently made changes to their positions in NEOG. Allspring Global Investments Holdings LLC increased its position in shares of Neogen by 142.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,982 shares of the company’s stock valued at $33,000 after buying an additional 1,165 shares in the last quarter. Headlands Technologies LLC grew its stake in Neogen by 264.1% in the 2nd quarter. Headlands Technologies LLC now owns 3,397 shares of the company’s stock valued at $53,000 after acquiring an additional 2,464 shares during the period. Neo Ivy Capital Management purchased a new stake in Neogen in the 3rd quarter worth $66,000. Marco Investment Management LLC acquired a new position in Neogen during the third quarter worth $169,000. Finally, Raymond James Trust N.A. purchased a new position in Neogen during the third quarter valued at $182,000. Institutional investors and hedge funds own 96.73% of the company’s stock.

Insider Activity at Neogen

In other Neogen news, CEO John Edward Adent acquired 14,500 shares of the firm’s stock in a transaction on Friday, October 11th. The stock was acquired at an average cost of $13.80 per share, for a total transaction of $200,100.00. Following the purchase, the chief executive officer now owns 216,477 shares in the company, valued at approximately $2,987,382.60. The trade was a 7.18 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.13% of the stock is owned by insiders.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.